Differentiated Thyroid Cancer (DTC) Recruiting Phase 2 Trials for Lenvatinib (DB09078)

Also known as: Differentiated Thyroid Cancer

IndicationStatusPhase
DBCOND0062237 (Differentiated Thyroid Cancer (DTC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03630120Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTreatment